US/UK/Canada

Share

Quotes

The article in Blood is a mark of quality and a milestone for the researchers. There is a considerable medical need for new cancer drugs and the development that is taking place within the framework of Vivolux is very much leading edge, as shown by Harvard Medical School and other leading institutions
Hans Rosén, Vivolux Chief Executive
The published mechanism of action is extremely interesting in the creation of new cancer drugs. We feel very excited about exploring the therapeutic potential of this new drug candidate in clinical studies. Our hope is that our joint research will lead to improved cancer treatment.
Dr. Dharminder Chauhan, Harvard Medical School
Pick a time period -
Tags ( Active)

Progress for Vivolux drug candidate VLX1570

Vivolux, a pharmaceutical company specialized in cancer treatment, announced today that the first patient in its ongoing Phase I/II study has successfully completed treatment at the third dose level of the drug candidate VLX1570.Vivolux has developed a drug which through a newly discovered mechanism blocks the proteasome, the cell degradation 'machine' for defective proteins. Large amounts of defective proteins form in tumor cells, making them vulnerable to disruption of proteasome function. The new mechanism of action by VLX1570 has been shown to inhibit tumor growth and prolong

Promising progress in Vivolux’ VLX600 Study

Vivolux, a pharmaceutical company specialized in cancer treatment, announced today that the first dose level of the ongoing VLX600 study has successfully been accomplished in its phase I/II-study.VLX600 is one of the company's promising projects, which was recently published in the journal Nature Communications. Researchers at Vivolux have discovered a novel cancer drug target. The drug candidate kills sleeping cell populations in regions of solid tumors that are metabolically compromised due to poor vascularization – areas that cannot be reached by conventional cancer therapeutics.

FDA grants clearance to proceed with clinical study – new drug candidate from Vivolux could overcome drug resistance

Vivolux, a pharmaceutical company specialized in cancer treatment, announced today that the FDA has granted clearance to proceed with VLX1570 to clinical phase I/II for treatment against relapsed and/or refractory multiple myeloma. Researchers at Vivolux have discovered a novel cancer drug target within the proteasome in tumor cells. This novel drug candidate inhibits tumor growth and prolongs survival in multiple myeloma in preclinical models that are resistant to conventional therapies.The clinical study will be conducted in collaboration with the Memorial Sloan-Kettering Cancer Center

FDA gives clearance to proceed with clinical study - new drug candidate from Vivolux starves cancer cells

Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that the FDA has granted clearance to proceed with VLX600 into the clinical phase I/II. VLX600 is one of the company's promising projects, and which was recently published in the journal Nature Communications. Researchers at Vivolux have discovered a novel cancer drug target. The drug candidate kills sleeping cell populations in regions of solid tumors that are metabolically compromised due to poor vascularization – areas that cannot be reached by conventional cancer therapeutics.The study will be

New drug candidate from Vivolux starves cancer cells – clinical study due to begin shortly

Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that data that forms the basis for one of the company's promising projects has been published in the journal Nature Communications. Researchers at Vivolux have discovered a novel cancer drug target. The drug candidate kills sleeping cell populations in regions of solid tumors that are less oxygenized – areas that cannot be reached by conventional cancer therapeutics.In solid tumors, there are areas with poor vascular supply where cancer cells divide more slowly due to a lack of oxygen and nutrients. The

Multiple myeloma first indication for drug candidate from Vivolux

Blood* publishes study on drug candidate for multiple myeloma that overcomes drug resistance by new mechanism of action.Vivolux AB, a company specialized in cancer treatment, announced today that data that forms the basis for one of the company's promising projects has been published in Blood, *) Journal of the American Society of Hematology.A research study led by the Dana-Farber Cancer Institute at Harvard Medical School, also involving the Karolinska Institute, has found that a novel drug candidate inhibits tumor growth and prolongs survival in multiple myeloma (MM) in preclinical

There are no items matching the current filter
There are no more items matching the current filter
Back to top